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 Overdose deaths in the United States continue to pose a significant threat, although 
provisional statistics suggest that overdose deaths may be declining.1  Most opioid-related deaths 
involve illicit substances, such as heroin and fentanyl.2  Conversely, opioid prescribing and 
overdose deaths related to prescription opioids have both declined significantly in recent years.3  
Nevertheless, the federal government has committed to further restricting the availability of 
prescription opioid medication.4  
 
 To that end, the Department of Justice (DOJ) has implemented an aggressive effort to 
shut down rogue prescribers and pharmacists.5  As part of this effort, however, the DOJ has 
raided, searched, and investigated a past president of the American Academy of Pain Medicine 
(AAPM), the editor-in-chief of the Practical Pain Management medical journal, the immediate 
past president of the American Society of Addiction Medicine (ASAM), and a past president of 
ASAM’s affiliate, the Tennessee Society of Addiction Medicine.6  None of these influential 
physicians has been charged with a crime.  
 
                                                
* Michael C. Barnes, Esq. is the managing partner of DCBA Law & Policy.  He obtained his 
Juris Doctor from George Mason University School of Law, 2002. 
1 See Aaron Glickman and Janet Weiner, Why Deaths Continue to Rise in the Opioid Epidemic, 
PENN LDI (Jan. 22, 2019), https://ldi.upenn.edu/healthpolicysense/why-deaths-continue-rise-
opioid-epidemic. But see Julia Jacobo, Drug-overdose Deaths on the Precipice of Declining for 
First Time in Decades, CDC Says, ABC NEWS (June 26, 2019), 
https://abcnews.go.com/US/drug-overdose-deaths-precipice-declining-time-decades-
cdc/story?id=63958453 (predicting that the number of drug-related deaths in 2018 was lower 
than in 2017, although the statistics have not been released). 
2 See id.  
3 CTR. FOR DISEASE CONTROL & PREVENTION, CHANGES IN OPIOID PRESCRIBING PATTERNS 
(2018), https://www.cdc.gov/drugoverdose/data/prescribing.html. 
4 See generally SUPPORT Act, Pub. L. No. 115-271 (2018). 
5 See infra, Part IIB.  
6 See infra, Part IIB.  
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 Indiscriminate raids, searches, and investigations of heath care professionals put patients’ 
lives at risk, destroy professionals’ livelihoods and careers, and create confusion, fear, and 
reluctance to prescribe among other health care professionals.  This chilling effect undermines 
congressional efforts to expand the number of professionals who prescribe medications to treat 
opioid use disorder (OUD).7 
 
To ensure that professionals feel confident prescribing or dispensing medication to treat 
opioid use disorder and other conditions that may require treatment with controlled medications, 
complaints against licensed health care professionals, including pharmacists, should be 
investigated first by professional licensing boards, which are governed and staffed by 
professionals with health-specific expertise, rather than by law enforcement.  
 
Congress and state legislators should, therefore, amend federal and state laws to require 
law enforcement to obtain a referral from the appropriate state health-profession licensing board 
before instituting, aiding in, or defending an investigation or criminal or civil action against a 
prescriber or dispenser of FDA-approved medications in which medical need or patient care, 




A. THE U.S. OVERDOSE CRISIS PRIMARILY INVOLVES SUBSTANCES OTHER THAN OPIOID
 PAIN RELIEVERS 
 
Substance abuse is among the most difficult of health and social problems to address.8  
The  nearly two-decade upward trend in drug overdose deaths, at 70,237 in 2017,9 illustrates the 
need for preventive and responsive measures.  Opioid analgesics were involved in most opioid-
related overdose deaths from 2002 until 2011.10  Opioid analgesic prescribing peaked in 2012 but 
decreased 28 percent by 2017.11  This decline reflects the fact that some health care providers 
                                                
7 See infra, Part IID.  
8 See SUBSTANCE ABUSE AND MENTAL HEALTH ADMIN., SUBSTANCE ABUSE AND MENTAL 
ILLNESS PREVENTION (2019), https://www.samhsa.gov/prevention (stating that substance use and 
mental disorders can make daily activities difficult and impair a person’s ability to work, interact 
with family and fulfil other major life functions).  
9 See NAT’L INST. ON DRUG ABUSE, OVERDOSE DEATH RATES 1 (FIG. 1) (2019), 
https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates.  
10 CTR. FOR DISEASE CONTROL & PREVENTION, INCREASES IN DRUG AND OPIOID OVERDOSE 
DEATHS – UNITED STATES, 2000-2014 (2016), 
https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6450a3.htm. 
11 CTR. FOR DISEASE CONTROL & PREVENTION, CHANGES IN OPIOID PRESCRIBING PATTERNS 
(2018), https://www.cdc.gov/drugoverdose/data/prescribing.html. 
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have ceased prescribing opioid analgesics altogether.12  Other healthcare providers have become 
more guarded in their opioid prescribing practices.13  
 
In the United States, the demand for illicit heroin and fentanyl rose due to restricted 
access to prescription opioids.14 Consequently,  the greater demand has yielded increases in illicit 
drug supply, abuse, addiction, and overdoses.15  Illicit opioids (e.g., analog fentanyl and heroin) 
are now the most common substances found in drug overdose fatalities.16  Not all individuals 
who consume these substances have intended to do so.  Analog fentanyl is often mixed with 
heroin or cocaine or pressed into counterfeit pills without the user’s knowledge.17  The Drug 
Enforcement Administration (DEA) has issued public warnings that pills being sold on the black 
market such as oxycodone, for example, are actually counterfeit drugs containing illicit 
fentanyl.18  Pharmaceutical fentanyl is 50 times more potent than heroin and 100 times more 
potent than morphine.19  An extremely deadly fentanyl analog detected in the U.S., carfentanil, is 
                                                
12 see Richard Lawhern, Stop Persecuting Doctors for Prescribing Opioids for Chronic Pain, 
Stat News (June 28, 2019), https://www.statnews.com/2019/06/28/stop-persecuting-doctors-
legitimately-prescribing-opioids-chronic-pain/.  
13 Gery P. Guy, Jr., et al., Vital Signs: Changes in Opioid Prescribing in the United States, 2006-
2015, 66 MMRW 697, 700 (2017)(describing the decreases in opioid prescribing levels due to 
studies that showed potential for overdose risk).  
14See RICHARD J. BONNIE, ET AL., PAIN MGMT. AND THE OPIOID EPIDEMIC: BALANCING SOCIETAL 
AND INDIVIDUAL BENEFITS AND RISKS OF PRESCRIPTION OPIOID USE 217 (2017), 
https://www.ncbi.nlm.nih.gov/books/NBK458661/. 
15 See id. at 2.  
16 Holly Hedegaard, Drugs Most Frequently Involved Drug Overdose Deaths, 2011-2016, 67 
NAT’L VITAL STATISTICS REPORTS 1, 4 (2018) (finding fentanyl accounted for 29% of all 
overdose deaths in 2016 and heroine accounted for 25% of overdose deaths).  
17 See R. Matthew Gladden et al., Fentanyl Law Enforcement Submissions and Increases in 
Synthetic Opioid-Involved Overdose Deaths – 27 States, 2013-2014, 65 MMRW 837, 837-38 
(2016). 
18 See Times Staff, DEA Warns Pills Being Sold on El Paso Streets as Oxycodone Actually 
Contain Fentanyl, EL PASO TIMES (Mar. 2, 2019), 
https://www.elpasotimes.com/story/news/crime/2019/03/02/pills-sold-el-paso-streets-
oxycodone-actually-contain-fentanyl/3039711002/.  
19 Gladden, supra note 17, at 838.  
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estimated to be 10,000 times more potent than morphine.20  
 
The demand for non-opioid substances of abuse has also increased, and stimulant- and 
benzodiazepine-related overdoses are on the rise.21  Almost 16 percent of college students say 
they misuse prescription stimulants, often in the quest for better grades.22  From 2014 to 2016, 
the number of overdose deaths involving cocaine nearly doubled from 5,892 to 11,316.23  The 
number of overdose deaths involving  methamphetamine increased 3.6-fold from 1,887 deaths in 
2011 to 6,762 deaths in 2016.24  
 
Twenty percent of college students say it is somewhat or very easy to obtain sedatives, 
which they report using most often for sleep or anxiety relief.25  An estimated 1.7 million 
Americans aged 12 or older misuse prescription tranquilizers, including benzodiazepines and 
muscle relaxants.26  More than 30 percent of overdoses involving opioids also involve 
benzodiazepines, and 23 percent of individuals who died of an opioid-related overdose also 
tested positive for benzodiazepines.27   
 
Let us not forget the harms of legal, non-controlled, non-prescription substances of abuse.  
                                                
20 See Julie K. O’Donnell et al., Trend in Death Involving Heroin and Synthetic Opioids 
Excluding Methadone, and Law Enforcement Drug Product Reports, by Census Region – United 
States, 2006-2015, 66 MMWR 897, 902 (2017).  
21 See Sarah Karlin-Smith and Brianna Ehley, 5 Unintended Consequences of Addressing the 
Opioid Crisis, POLITICO (May 8, 2018),  https://www.politico.com/story/2018/05/08/opioid-
epidemic-consequences-502619 (finding that deaths involving cocaine increased 52.4% between 
2015 and 2016); Marcus A. BachHuber et al., Increasing Benzodiazepine Prescriptions and 
Overdose Mortality in the United States, 106 AM. J. PUBLIC HEALTH 686, 686-87 (2016). 
22 See OHIO STATE UNIVERSITY, COLLEGE PRESCRIPTION DRUG STUDY 2018 RESEARCH BRIEF - 
STIMULANT USE 1 (2018), https://cssl.osu.edu/posts/632320bc-704d-4eef-8bcb-
87c83019f2e9/documents/cpds-brief-stimulants-final.pdf. 
23 See Hedegaard, supra note 16, at 4.  
24 See Hedegaard, supra note 16, at 4.  
25 See OHIO STATE UNIVERSITY, COLLEGE PRESCRIPTION DRUG STUDY KEY FINDINGS 2 (2018), 
https://cssl.osu.edu/posts/632320bc-704d-4eef-8bcb-87c83019f2e9/documents/cpds-2018-key-
findings-final.pdf.  
26 See SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMIN., KEY SUBSTANCE USE AND 
MENTAL HEALTH INDICATORS IN THE UNITED STATES: RESULTS FROM THE 2017 NATIONAL 
SURVEY ON DRUG USE AND HEALTH 16 (2018). 
27 See NAT’L INSTITUTE ON DRUG ABUSE, BENZODIAZEPINES AND OPIOIDS (2018), 
https://www.drugabuse.gov/drugs-abuse/opioids/benzodiazepines-opioids. 
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More than 88,000 Americans die from alcohol-related causes annually.28  Cigarette smoking 
contributes to more than 480,000 deaths annually.29  The FDA has declared the use of e-
cigarettes, which contain addictive nicotine, an epidemic among teens with use increasing 78 
percent from 2017 to 2018.30   
 
B. The Federal Government Is Still Focusing Intensely on Reducing Opioid Prescribing 
 
Policy efforts to address drug abuse, addiction, and overdose in the U.S. remain largely 
focused on restricting access to opioid analgesics.31  On top of existing reductions in opioid 
analgesic prescribing, the federal government is seeking to cut nationwide opioid prescription 
fills by an additional one-third by 2021.32  
 
The Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment 
for Patients and Communities Act (SUPPORT Act), enacted on October 24, 2018, illuminates 
the federal focus on reducing exposure to opioid analgesics.33  The provisions of  the SUPPORT 
Act that further restrict access to prescription pain relievers include:  
• Granting the U.S. Food and Drug Administration (FDA) authority to require alterations to 
opioid analgesic packaging (e.g., blister packs);34  
• Developing guidance for hospitals on how to reduce opioid analgesic use;35 and 
• Granting additional authority to the DEA to change nationwide prescription opioid 
quotas.36  
                                                
28 NAT’L INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM, ALCOHOL FACTS AND STATISTICS 
(2018), https://www.niaaa.nih.gov/alcohol-health/overview-alcohol-consumption/alcohol-facts-
and-statistics. 
29 CTR. FOR DISEASE CONTROL & PREVENTION, SMOKING AND TOBACCO USE (2018), 
https://www.cdc.gov/tobacco/data_statistics/fact_sheets/health_effects/tobacco_related_mortality
/index.htm (including deaths from second hand smoke). 
30 Karen A. Cullen at al., Use of Electronic Cigarettes and Any Tobacco Product Among Middle 
and High School Students – United States, 2011-2018, 67 MMRW 1276, 1276 (2018).  
31 See, e.g., SUPPORT Act, Pub. L. No. 115-271 (2018). 
32 Press Release, The White House, President Donald J. Trumps Initiative to Stop Opioid Abuse 
and Reduce Drug Supply and Demand (Oct. 24, 2018). 
33 See generally SUPPORT Act, Pub. L. No. 115-271 (2018).  
34 See SUPPORT Act, Pub. L. No. 115-271, § 3041 (2018).  
35 See SUPPORT Act, Pub. L. No. 115-271, § 6092 (2018). 
36 See SUPPORT Act, Pub. L. No. 115-271, § 3282 (2018). 




The SUPPORT Act supplemented preexisting federal efforts with the same objective.  
Current high-profile federal initiatives include: the Centers for Disease Control and Prevention 
(CDC) Guideline for Prescribing Opioids for Chronic Pain in primary care;37 the Department of 
Justice (DOJ) Opioid Fraud and Abuse Detection Unit,38 Prescription Interdiction & Litigation 




1. DOSE AND DURATION LIMITS 
 
The CDC published a guideline for opioid prescribing for chronic pain in primary care 
settings in 2016.41  The guideline suggests limits on the dose and duration of opioid prescriptions 
to prevent patients from developing OUD.42  At least 33 states have since enacted dosage- or 
duration-limiting laws for opioid analgesic prescriptions.43  
 
2. AGGRESSIVE DOJ ENFORCEMENT 
 
In 2017, the DOJ established the Opioid Fraud and Abuse Detection Unit to mine 
prescribing and dispensing data to identify suspicious patterns and practices, then target and 
prosecute individuals who contribute to the overdose epidemic.44  In February 2018, the DOJ 
                                                
37 Deborah Dowell, et al., CDC Guideline for Prescribing Opioids for Chronic Pain - United 
States, 2016, 65 MMRW 1 (2016).    
38 Press Release, Department of Justice, Attorney General Sessions Announces Opioid Fraud and 
Abuse Protection Unit (Aug. 2, 2017) [hereinafter Fraud and Abuse Detection Unit]. 
39 See Press Release, Department of Justice, Attorney General Announces New Prescription 
Interdiction & Litigation Task Force (Feb. 27, 2018) [hereinafter PIL]. 
40 Press Release, Department of Justice, Justice Department’s Criminal Division Creates 
Appalachian Regional Prescription Opioid Strike Task Force to Focus on Illegal Opioid 
Prescriptions (Oct. 25, 2018) [hereinafter ARPOST]. 
41 See generally Deborah Dowell, et al., CDC Guideline for Prescribing Opioids for Chronic 
Pain - United States, 2016, 65 MMRW 1 (2016).    
42 See id. at 15.  
43 See Prescribing Policies: States Confront Opioid Epidemic, NATIONAL CONFERENCE OF STATE 
LEGISLATURES (Oct. 31, 2018), http://www.ncsl.org/research/health/prescribing-policies-states-
confront-opioid-overdose-epidemic.aspx. 
44 See Fraud and Abuse Protection Unit, supra note 38.  
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expanded upon the Opioid Fraud and Abuse Detection Unit, bringing together senior DOJ 
officials under the umbrella of the PIL Task Force “to use all criminal and civil tools at its 
disposal” to crack down on manufacturers, distributors, pharmacies, pain management clinics, 
drug testing facilities, and individual health care providers.45  In October 2018, the DOJ formed 
the Prescription Opioid Strike Force to prosecute medical professionals and others involved in 
the illegal prescription and distribution of opioids.46  The Federal Bureau of Investigation (FBI) 
and U.S. Department of Health and Human Services (DHHS) Office of the Inspector General 
(OIG) are part of the Strike Force.47   
 
The Department of Justice as well as state and local law enforcement have found success 
convicting opioid prescribers for unambiguously criminal misconduct, including murder if their 
patients die of an overdose involving the opioids they prescribed.48  Dr. Hsiu-Ying “Lisa” Tseng 
and Dr. Michael Alson Smith are two examples of “dirty docs” who have been convicted.49  
 
In 2016, Dr. Tseng, an osteopathic physician licensed in California and referred to as “Dr. 
Feelgood,” was sentenced to 30 years to life in prison for second-degree murder of three of her 
patients who had fatal overdoses.50  She appealed, and in December 2018, California’s Second 
District Court of Appeals upheld her conviction, finding overwhelming evidence of her 
knowledge of risk and reckless indifference to her patients’ lives in her prescribing practices.51  
Tseng was reportedly the first U.S. doctor convicted of murder for improperly prescribing 
controlled medications.52 
 
In February 2019, Dr. Smith, a former North Carolina physician, was sentenced to three 
                                                
45 See PIL, supra note 39.  
46 See ARPOST, supra note 40.  
47 See id.  
48 See, e.g., People v. Tseng, 241 Cal. Rptr. 3d 194, 208 (Cal. Ct. App. 2018); Press Release, 
Doctor Convicted of Three Murders in Prescription Drug Overdose Case (Oct. 30, 2015), 
https://www.dea.gov/press-releases/2015/10/30/doctor-convicted-three-murders-prescription-
drug-overdose-case. 
49 See, e.g., id. 
50 See Felice J. Freyer, Doctor Charged with Manslaughter in Opioid Overdose Death, BOS. 
GLOBE (Dec. 11, 2018), https://www.bostonglobe.com/metro/2018/12/11/doctor-charged-with-
manslaughter-opioid-overdose-death/2h5j03vXdFHBDZqPiQDZVN/story.html.   
51 See People v. Tseng, 241 Cal. Rptr. 3d 194, 208 (Cal. Ct. App. 2018).  
52 Press Release, Doctor Convicted of Three Murders in Prescription Drug Overdose Case (Oct. 
30, 2015), https://www.dea.gov/press-releases/2015/10/30/doctor-convicted-three-murders-
prescription-drug-overdose-case. 
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years in federal prison after pleading guilty to illegal drug distribution, health care fraud, and 
aggravated identity theft in connection with the illegal distribution of controlled medications to 
at least seven patients in exchange for sex acts in 2017.53  DOJ prosecutors alleged that Smith 
coerced patients to engage in sexual acts by threatening to stop prescribing controlled 
medication.54  Prosecutors further alleged that Smith submitted fraudulent claims to, and was 
paid by, North Carolina Medicaid and Medicare, for medical services he did not provide during 
the office visits in which sex acts with patients took place.55 
 
The DOJ is aggressively fulfilling its vow to “use every criminal, civil, and regulatory 
tool possible to target, prosecute and shut down” entities whose conduct it deems unlawful.56  
During a 45-day “surge” in 2018, the DOJ made 28 arrests and took 337 other investigative and 
administrative actions, including executing searches, conducting inspections, obtaining voluntary 
surrenders of DEA registrations, and issuing orders to show cause why registration should not be 
revoked and immediate suspension orders.57 
 
On February 8, 2019, the DOJ announced that its PIL Task Force had, for the first time, 
obtained an ex parte temporary restraining order (TRO) from the U.S. District Court for the 
Middle District of Tennessee to stop two pharmacies, their owner, and three pharmacists from 
dispensing opioids and other controlled medications.58  The defendants were not provided notice 
or an opportunity to appear before the court before it issued the TRO.59  According to the 
unsealed complaint, the pharmacies and pharmacists allegedly filled prescriptions for controlled 
                                                
53 Joe Marusak, NC Doctor Who Traded Drugs for Sex with Patients Receives Prison Sentence, 
CHARLOTTE OBSERVER (Feb. 21, 2019), 
https://www.charlotteobserver.com/news/local/crime/article226567114.html. 
54 Press Release, Department of Justice, Former North Carolina Physician Pleads Guilty to Drug 
Distribution, Health Care Fraud, and Aggravated Identify Theft Charges (June 1, 2018), 
https://www.justice.gov/usao-wdnc/pr/former-north-carolina-physician-pleads-guilty-drug-
distribution-health-care-fraud-and.  
55 Id.  
56 Press Release, Drug Enforcement Administration, DEA Surge and Drug Diversion 
Investigations Lead to 28 Arrests and 147 Revoked Registrations (April 2, 2018), 
https://www.dea.gov/press-releases/2018/04/02/dea-surge-drug-diversion-investigations-leads-
28-arrests-and-147-revoked. 
57 Id.  
58 T.R.O. at 2, 3, United States v. Oakley Pharmacy, Inc., No. 2:19-cv-00009 (M.D. Tenn. Feb. 
7, 2019). 
59 T.R.O. at 1, United States v. Oakley Pharmacy, Inc., No. 2:19-cv-00009 (M.D. Tenn. Feb. 7, 
2019) (indicating the temporary restraining order was under seal).  
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medications outside the ordinary course of professional conduct without having verified that the 
prescriptions were issued for a legitimate medical need.60  Specifically, the complaint alleged 
that the defendants routinely dispensed opioids in high doses, in dangerous combinations with 
other controlled medications, and to patients who traveled long distances to obtain and fill 
prescriptions.61  
 
C. FEDERAL RAIDS ARE NOT LIMITED TO PRESCRIBERS AND DISPENSERS OF OPIOID 
ANALGESICS  
 
DOJ and its federal enforcement partners are also targeting prescribers of FDA approved 
medications used to treat OUD.62  Such medications include methadone, naltrexone, and 
buprenorphine.63  Presently, only one-third of substance use disorder treatment programs offer 
medication.64  
Methadone is an FDA approved controlled opioid.65  When used to treat OUD it may be 
dispensed only in federally regulated methadone clinics.66  Naltrexone is not a controlled 
medication and has a relatively low potential for diversion and abuse.67  Naltrexone-assisted 
treatment cannot begin until an individual has stopped using opioids for seven to 10 days.68  
                                                
60 Complaint at 1, United States v. Oakley Pharmacy, Inc., No. 2:19-cv-00009 (M.D. Tenn. Feb. 
7, 2019). 
61 See id. at 29-30, 33. 
62 See Maia Szalavitz, The Feds Are Raiding the Offices of Doctors Who Prescribe Addiction 
Medication, VICE (June 6, 2018), https://www.vice.com/en_us/article/8xevwb/dea-raids-
addiction-doctors (describing the FBI raid of Dr. Stuart Gitlow home and office).  
63 SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMIN, MEDICATION ASSISTED 
TREATMENT (2019), https://www.samhsa.gov/medication-assisted-
treatment/treatment#medications-used-in-mat.  
64 Sheila Kaplan, F.D.A. to Expand Medication-Assisted Therapy for Opioid Addicts, N.Y. TIMES 
(Feb. 25, 2018), https://www.nytimes.com/2018/02/25/science/fda-medication-assisted-
therapy.html?module=ArrowsNav&contentCollection=Health&action=keypress&region=FixedL
eft&pgtype=article 
65 SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMIN., METHADONE (2015), 
https://www.samhsa.gov/medication-assisted-treatment/treatment/methadone. 
66 Id. 
67 SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMIN., CLINICAL USE OF EXTENDED-
RELEASE INJECTABLE NALTREXONE IN THE TREATMENT OF OPIOID USE DISORDER: A BRIEF 
GUIDE 6 (2015).  
68 Id. at 12-13. 
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Naltrexone’s effects can yield a sudden reduction in tolerance to opioids.69  After a patient 
receives treatment with naltrexone, the use of previously tolerated doses of opioids could lead to 
overdose.70   
 
Buprenorphine is a controlled opioid that effectively fills opiate receptors in the brain, 
thereby reducing opioid withdrawal symptoms and cravings without increasing opioid sensitivity 
and the risk of overdose.71  Buprenorphine is safer than commonly prescribed opioid analgesics 
because of a phenomenon called the “ceiling effect,” which prevents intoxication and respiratory 
depression among opioid-tolerant individuals and reduces the possibilities for both abuse and 
overdose.72  To prevent diversion and abuse of buprenorphine, the Drug Addiction Treatment 
Act of 2000 (DATA 2000) requires providers who seek authority to prescribe buprenorphine to 
patients with OUD to obtain a waiver.73  DATA 2000 also limits the number of patients they may 
treat at any one time.74 
 
Opioid-tolerant individuals have a lower likelihood of overdosing on buprenorphine than 
other prescription or illicit opioids,75 and individuals who obtain buprenorphine on the black-
market use it primarily to relieve OUD withdrawal symptoms.76  Relatively few people use 
                                                
69 See AMY GIBSON AND LOUISA DEGENHARDT, NAT’L DRUG & ALCOHOL RESEARCH CENTRE, 
MORTALITY RELATED TO NALTREXONE IN THE TREATMENT OF OPIOID DEPENDENCE: A 
COMPARATIVE ANALYSIS, xviii (2005).  
70 NAT’L DRUG AND ALCOHOL RESEARCH CTR., MORTALITY RELATED TO NALTREXONE IN THE 
TREATMENT OF OPIOID DEPENDENCE: A COMPARATIVE ANALYSIS xii (2005) (finding that the 
lack of naltrexone exposes a naltrexone-maintained patient to overdose risk). 
 
71 NAT’L DRUG AND ALCOHOL RESEARCH CTR., MORTALITY RELATED TO NALTREXONE IN THE 
TREATMENT OF OPIOID DEPENDENCE: A COMPARATIVE ANALYSIS 10 (2005). See also, Sonia 
Mendoza, et al. Shifting Blame: Buprenorphine Prescribers, Addiction Treatment, and 
Prescription Monitoring in Middle-Class America, 53 TRANSCULT PSYCHIATRY 465 (2016) 
(linking the FDA’s approval of buprenorphine with the increased use of opioids by middle-class 
America). 
72 See SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMIN., CLINICAL GUIDELINES FOR 
THE USE OF BUPRENORPHINE IN THE TREATMENT OF OPIOID ADDICTION 15 (2004).  
73 Id., at 133. 
74 Id. 
75 See Jake Harper, Black Market for Suboxone Gives Some a Glimpse of Recovery, KAISER 
HEALTH NEWS (Oct. 9, 2018), https://khn.org/news/black-market-for-suboxone-gives-some-a-
glimpse-of-recovery/.  
76 See id. 
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buprenorphine to get high.77  For these and other reasons, practitioners are calling for the 
deregulation of buprenorphine for the treatment of OUD.78  Nevertheless, the DOJ investigates 
and prosecutes prescribers of buprenorphine for OUD using the same tactics it uses in pursuit of 
prescribers and dispensers of opioid analgesics.79  
 
D. THE DEPARTMENT OF JUSTICE HAS RAIDED SOME OF AMERICA’S MOST REPUTABLE 
PHYSICIANS 
 
The professionals whose conduct the DOJ deems unlawful are, in some cases, among the 
most reputable physicians in the U.S.80  Some of these professionals have presided over the 
organizations that draft and publish guidelines and other medical-scientific literature that form 
the basis of the medical standard of care.81  
 
1. DR. LYNN WEBSTER, PAST PRESIDENT OF THE AMERICAN ACADEMY OF PAIN MEDICINE 
 
In 2010, the DEA raided the Utah clinic of Dr. Lynn Webster,82 a physician with board 
certifications in anesthesiology, pain medicine, and addiction medicine.83  Webster lectures 
extensively on the subject of preventing opioid abuse and criminal diversion in the treatment of 
pain and has authored more than 300 scientific abstracts, manuscripts, journal articles, and 
books.84  He is a past president of AAPM,85 which develops clinical practice guidelines for use 
                                                
77 See id. 
78 See id. (quoting a doctor who believes more regulation will cause addicts to turn to the street).  
79 Press Release, Five Pennsylvania Physicians Charged with Unlawfully Distributing 
Buprenorphine and Defrauding Medicare and Medicaid (May 3, 2018), 
https://www.justice.gov/opa/pr/five-pennsylvania-physicians-charged-unlawfully-distributing-
buprenorphine-and-defrauding 
80 See Daphne Chen & Eric Schulzke, Two Utah Doctors Caught in Spotlight of Opioid 
Lawsuits, DESERET NEWS (June 6, 2017), https://www.deseretnews.com/article/865681412/Two-
Utah-doctors-caught-in-spotlight-of-opioid-lawsuits.html. 
81 See id.  
82 Christopher Moraff, Feds’ Pill Crackdown Drives Pain Patients to Heroin, DAILY BEAST 
(Apr. 15, 2016), https://www.thedailybeast.com/feds-pill-crackdown-drives-pain-patients-to-
heroin. 
83 Who is Dr. Lynn Webster, DR. LYNN WEBSTER, http://www.lynnwebstermd.com/about/ (last 
visited Jul. 17, 2019). 
84 Id. 
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of opioids in the treatment of pain drawing upon clinicians’ expertise and literature reviews.86  
 
The DOJ spent four years investigating Webster, during which time media attention 
negatively impacted his practice.87  Specifically, in a December 2013 CNN report, Dr. Sanjay 
Gupta referred to Webster repeatedly as “Dr. Death.”88  In June 2014, the DOJ announced that it 
would not prosecute Webster.89  “My reputation was tarnished forever,” Webster said in 2016.90  
 
2. DR. FOREST TENNANT, EDITOR-IN-CHIEF OF PRACTICAL PAIN MANAGEMENT 
 
In 2017, DEA agents raided the home and offices of Dr. Forest Tennant after having 
already investigated the pain physician for two years.91  For a decade, Tennant served as editor-
in-chief of the Practical Pain Management medical journal, which provides research insights 
and information on best practices in pain medicine.92  Tennant also served as mayor of West 
Covina, California.93  In 2017, Tennant’s peers honored him with a lifetime achievement award 
for his contributions to pain medicine.94 
                                                                                                                                                       
85 AAPM Council of Past Presidents, AM. ACAD. PAIN MGMT., 
https://painmed.org/about/board/council-of-past-presidents (last visited Jul. 17, 2019). 
86 Id. 
87 See Moraff, supra note 81. 
88 Id. 
89 Lynn Webster, DEA Ends Investigation of Pain Doctor, DR. LYNN WEBSTER (Sept. 4, 2014), 
http://www.lynnwebstermd.com/dea-ends-investigation-of-pain-doctor/. 
90 Moraff, supra note 81. 
91 Pat Anson, DEA Raids Dr. Forest Tennantt’s Patient Clinic, PAIN NEWS NETWORK (Nov. 16, 
2017), https://www.painnewsnetwork.org/stories/2017/11/16/dea-raids-forest-tennants-pain-
clinic. 
92 About Forest Tennant, MD, DrPH, PRAC. PAIN MGMT., 
https://www.practicalpainmanagement.com/author/2391/tennant (last visited July 17, 2019); 
About Practical Pain Management, PRAC. PAIN MGMT, 
https://www.practicalpainmanagement.com/about (last visited Jul. 17, 2019). 
93 Brian Day & Stephanie K. Baer, DEA Targets Former West Covina Mayor in Opioid 
Investigation, SAN GABRIEL VALLEY TRIB. (Nov. 16, 2017), 
https://www.sgvtribune.com/2017/11/16/dea-targets-former-west-covina-mayor-in-opioid-
investigation/.  
94 Jodi Godfrey, Forest Tennant, MD, DrPH, Honored for a Lifetime of Achievement in Pain 
Medicine, PRAC. PAIN MGMT., https://www.practicalpainmanagement.com/meeting-
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Tennant typically treated individuals with cancer or other complex conditions who 
otherwise had difficulty obtaining effective treatment.95  Months after the raid, the DEA 
reportedly had not found sufficient evidence to charge Tennant with a crime, but he retired 
nonetheless in 2018 due to the stress the ongoing investigation caused.96  One patient of Tennant 
said, “I believe many of Dr. Tennant’s patients will die because they will never find another 
doctor to treat their painful condition.”97 
 
3. DR. STUART GITLOW, PAST PRESIDENT OF THE AMERICAN SOCIETY OF ADDICTION 
MEDICINE 
 
In March 2018, FBI agents raided the Rhode Island medical office and home of Dr. 
Stuart Gitlow.98  Gitlow is a board-certified addiction psychiatrist and the immediate past 
president of ASAM.99  ASAM is a medical society representing over 6,000 addiction medicine 
professionals and is one of only five national associations that Congress has approved to provide 
the training that physicians must complete to obtain a federal waiver to treat OUD with 
buprenorphine.100  ASAM formulated the National Practice Guideline for the Use of 
Medications in the Treatment of Addiction Involving Opioid Use, which recommends standards 
and identifies best practices for addiction treatment practitioners.  As of July 2019, the DOJ’s 
investigation of Gitlow remained active.101   
 
4. DR. RALPH T. REACH, PAST PRESIDENT OF THE TENNESSEE SOCIETY OF ADDICTION 
                                                                                                                                                       
summary/forest-tennant-md-drph-honored-lifetime-achievement-pain-medicine (last visited Jul. 
17, 2019). 
95 Pat Anson, Dr. Forest Tennant Retiring Due to DEA Scrutiny, PAIN NEWS NETWORK (Mar. 26, 
2018), https://www.painnewsnetwork.org/stories/2018/3/26/dr-forest-tennant-retiring-due-to-
dea-scrutiny.  
96 T.C. Kelly, Has the Opioid Crisis Resulted in the Unfair Prosecution of Doctors?, 
FREEADVICE (Apr. 19, 2018), https://www.freeadvice.com/news/Litigation/has-the-opioid-crisis-
resulted-in-the-unfair-prosecution-of-doctors.htm. 
97 Anson, supra note 89. 




100 21 U.S.C. § 823 (g)(2)(G)(ii)(IV) (2012). 
101 Barnes phone conversation w/ Dr. Gitlow, Feb. 2019.  





In May 2018, the DEA raided and searched the home and clinics of Dr. Ralph T. Reach, a 
past president of the Tennessee Society of Addiction Medicine and a member of ASAM’s 
legislative committee who helped draft Tennessee’s OUD treatment law.102  As of March 2019, 
despite the fact that Reach had not been convicted of or even charged with a crime, he was 
unable to find a job practicing medicine.  “No one will employ me as long as I am under 
investigation,” he said. 
 
 
II. ANALYSIS  
 
A. INDISCRIMINATE RAIDS ARE DESTRUCTIVE  
 
DOJ raids and searches of professionals’ homes and medical clinics interrupt the delivery 
of health care, put patients’ lives at risk, and unjustly destroy careers and livelihoods.103  They 
also create confusion and fear among professionals serving or considering serving similar patient 
populations.104  A reluctance to practice and prescribe controlled medications when medically 
necessary is especially troublesome given rising rates of suicide, the availability of increasingly 
lethal black-market alternatives, and in the case of medications for OUD, the federal objective of 
increasing, rather than decreasing, their prescribing.105  
 
1. INABILITY OF STABLE PATIENTS TO OBTAIN NECESSARY MEDICATIONS 
 
Confused about new state dose and duration limits and fearing criminal and civil liability, 
some prescribers “report feeling pressure to lower patient doses, even for patients who have been 
on stable regimens of opioids for years without trouble.”106  According to Dr. Julian Grove, a 
pain specialist licensed to practice in Arizona, “[a] lot of practitioners are reducing opioid 
medications, not from a clinical perspective, but more from a legal and regulatory perspective for 
                                                
102 Julie Miller, Raids Cause Larger Concern for MAT Prescriber, BEHAV. HEALTHCARE 
EXECUTIVE (May 31, 2018), https://www.behavioral.net/article/policy/raids-cause-larger-
concern-mat-prescribers. 
103 See Moraff, supra note 81. 
104 See id. 
105 See id. 
106 Will Stone, Patients with Chronic Pain Feel Caught in an Opioid-Prescribing Debate, 
KAISER HEALTH NEWS (Aug. 1, 2018), https://www.healthleadersmedia.com/clinical-
care/patients-chronic-pain-feel-caught-opioid-prescribing-debate. 
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fear of investigation. No practitioner wants to be the highest prescriber.”107 
 
The Comprehensive Addiction and Recovery Act of 2016 (CARA) required DHHS, the 
Department of Veterans Affairs (VA), and the Department of Defense (DOD) to convene the 
Pain Management Best Practices Inter-Agency Task Force (Task Force) to identify gaps in best 
practices adopted by federal agencies for pain management.108  In May 2019, the Task Force 
published a final report, which stated, “regulatory oversight has also led to fears of prescribing 
among some clinicians, with some refusing to prescribe opioids even to established patients on a 
stable opioid regimen.”109  The report states that tightening the availability of opioid analgesics 
has “led to unintended consequences, such as patient abandonment and forced tapering.”110  
 
On March 6, 2019, more than 300 medical experts, including three former Directors of 
the Office of National Drug Control Policy, sent a letter to the CDC urging the agency to 
investigate increases in illicit opioid use and suicide following involuntary opioid taper or 
discontinuation premised upon the CDC’s recommendation.111  The experts asked the CDC to 
issue a bold clarification that the guideline does not endorse mandated involuntary dose 
reduction or discontinuation.112  On April 9, 2019, the FDA warned that abrupt opioid 
discontinuation can cause severe harm, including withdrawal symptoms, uncontrolled pain, 
psychological distress, and suicide.113  The following day, the CDC issued a clarification stating 
that the guideline recommends tapering opioid dosage “only when patient harm outweighs 
                                                
107 Id. 
108 Charter: Pain Management Best Practices Inter-Agency Task Force, U.S. DEP’T HEALTH & 
HUMAN SERVS., https://www.hhs.gov/ash/advisory-committees/pain/charter/index.html (last 
visited Jul. 17, 2019). 
109 Pain Management Best Practices Inter-Agency Task Force, Final Report on Pain 
Management Best Practices Inter-Agency Task Force Report, 12, U.S. DEP’T HEALTH & HUMAN 
SERVS. (May 6, 2019), https://www.hhs.gov/sites/default/files/pain-mgmt-best-practices-draft-
final-report-05062019.pdf (last visited Jul. 17, 2019). 
110 Id.  
111 Letter from Health Professionals for Patients in Pain (HP3), to Ctrs. for Disease Control & 
Prevention (Mar. 6, 2019), https://healthprofessionalsforpatientsinpain.org/the-letter-1 
112 Id.  
113 FDA Identifies Harm Reported From Sudden Discontinuation of Opioid Pain Medicines and 
Requires Label Changes to Guide Prescribers on Gradual, Individualized Tapering, FOOD & 
DRUG ADMIN. https://www.fda.gov/drugs/drug-safety-and-availability/fda-identifies-harm-
reported-sudden-discontinuation-opioid-pain-medicines-and-requires-label-changes (last visited 
Jul. 19, 2019). 
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patient benefit of opioid therapy.”114   
 
2. RELEGATION TO RISKY STREET DRUGS 
 
Patients who cannot access medically necessary controlled medications may turn to the 
black market in attempts to obtain relief from their untreated symptoms.115  At a time when 
counterfeit pills can be made to look like regulated pharmaceutical pain relievers,116 a patient 
desperate for treatment could unwittingly ingest deadly analog fentanyl.  Synthetic opioids, 
which include fentanyl and its analogs, contributed to nearly 30,000 overdose deaths in 2017, an 




Nearly 45,000 lives are lost in the U.S. each year to suicide,118 making it the tenth leading 
cause of death nationwide.119  The number of Americans who died by suicide after having 
medically necessary opioid pain relievers tapered without their consent or denied altogether is 
                                                
114 Letter to Daniel P. Alford, from Robert R. Redfield, Director, Ctr. For Disease Control & 
Prevention (April 10, 2019) available at https://img1.wsimg.com/blobby/go/3d70257f-a143-
4a5b-b9df-f7d265df0d3d/downloads/Alford%20Final%20.pdf?ver=1556148791199; see also, 
Press Release, CDC Advises Against Misapplication of the Guideline for Prescribing Opioids for 
Chronic Pain, Ctrs. for Disease Control & Prevention (Apr. 24, 2019) (updated on June 5, 2019), 
https://www.cdc.gov/media/releases/2019/s0424-advises-misapplication-guideline-prescribing-
opioids.html (noting that the CDC’s 2019 Guideline “does not support abrupt tapering or sudden 
discontinuation of opioids.”). 
115 2017 CDC Survey Results, PAIN NEWS NETWORK, https://www.painnewsnetwork.org/2017-
cdc-survey/ (last visited Jul. 17, 2019). 
116 Katie Zezima, Counterfeit Opioid Pills Are Tricking Users – Sometimes with Lethal Results, 
WASH. POST (Nov. 19, 2017), https://www.washingtonpost.com/national/counterfeit-opioid-pills-
are-tricking-users--sometimes-with-lethal-results/2017/11/19/d34edb14-be4b-11e7-8444-
a0d4f04b89eb_story.html. 
117 Christopher Ingraham, Fentanyl Use Drove Drug Overdose Deaths to a Record High in 2017, 
CDC Estimates, WASH. POST (Aug. 15, 2018), 
https://www.washingtonpost.com/business/2018/08/15/fentanyl-use-drove-drug-overdose-
deaths-record-high-cdc-estimates/?utm_term=.4707dbf14be0.  
118 Suicide Rising Across the US, CTRS. FOR DISEASE CONTROL & PREVENTION: VITAL SIGNS 
(June 2018), https://www.cdc.gov/vitalsigns/pdf/vs-0618-suicide-H.pdf.  
119 Melanie Heron, Deaths: Leading Causes for 2016, 67 NAT’L VITAL STATS. REP., at 8 (July 26, 
2018), https://www.cdc.gov/nchs/data/nvsr/nvsr67/nvsr67_06.pdf.  
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unknown.120  Researchers from the CDC looked at over 123,000 suicides in 18 states between 
2003 and 2014 and discovered that approximately 10 percent of those who died either had 
chronic pain in their medical records or mentioned it in suicide notes.121 
 
B. ROUGHSHOD RAIDS ARE COUNTERPRODUCTIVE 
 
While the federal government intends to decrease opioid analgesic prescription fills by an 
additional one-third by 2021,122 that is not the case with medications to treat OUD.123  The 
federal government has prioritized increasing patient access to medication for the treatment of 
OUD, as well as boosting the number of health care professionals who prescribe medication for 
OUD.124  
 
1. CONGRESSIONAL INTENT 
 
CARA expanded the types of providers who may treat individuals with buprenorphine for 
                                                
120 Elizabeth Llorente, As Doctors Taper or End Opioid Prescriptions, Many Patients Driven to 
Despair, Suicide, FOX NEWS (Dec. 10, 2018), https://www.foxnews.com/health/as-opioids-
become-taboo-doctors-taper-down-or-abandon-pain-patients-driving-many-to-suicide. 
121 See Pat Anson, One in 10 Suicides Linked to Chronic Pain, PAIN NEWS NETWORK (Sept. 12, 
2018), https://www.painnewsnetwork.org/stories/2018/9/12/one-in-10-suicides-linked-to-
chronic-pain; Emiko Petrosky et al., Chronic Pain Among Suicide Decedents, 2003 to 2014: 
Findings From the National Violent Death Reporting System, ANNALS OF INTERNAL MED. (Oct. 
2, 2018), http://annals.org/aim/fullarticle/2702061/chronic-pain-among-suicide-decedents-2003-
2014-findings-from-national. 
122 See Fact Sheets: President Donald J. Trump’s Initiative to Stop Opioid Abuse and Reduce 
Drug Supply and Demand, WHITE HOUSE (Oct. 24, 2018), 
https://www.whitehouse.gov/briefings-statements/president-donald-j-trumps-initiative-stop-
opioid-abuse-reduce-drug-supply-demand-2/.  
123 See Information about Medication-Assisted Treatment (MAT), FOOD & DRUG ADMIN. (Feb. 
14, 2019), https://www.fda.gov/drugs/information-drug-class/information-about-medication-
assisted-treatment-mat; FDA in Brief: FDA Finalizes New Policy to Encourage Widespread 
Innovation and Development of New Buprenorphine Treatments for Opioid Use Disorder, FOOD 
& DRUG ADMIN. (Feb. 6, 2018), https://www.fda.gov/news-events/fda-brief/fda-brief-fda-
finalizes-new-policy-encourage-widespread-innovation-and-development-new-buprenorphine. 
124 OFFICE OF NAT’L DRUG CTL. POLICY, EXEC. OFFICE OF THE PRESIDENT, NATIONAL DRUG 
CONTROL STRATEGY, at 9 (2019), https://www.whitehouse.gov/wp-
content/uploads/2019/01/NDCS-Final.pdf.  
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OUD to include nurse practitioners and physician assistants.125  The SUPPORT Act of 2018 
made two additional changes intended to expand access to buprenorphine for OUD.126  First, it 
enabled clinical nurse specialists, certified nurse midwives, and certified registered nurse 
anesthetists to obtain a waiver to prescribe buprenorphine for OUD.127  Second, it allowed 
federally waived practitioners to immediately start treating 100 OUD patients at a time with 
buprenorphine (skipping the initial 30 patient limit) if the practitioner is board certified in 
addiction medicine or addiction psychiatry, or if the individual practices in a qualified setting.128  
 
2. PRACTITIONER CONCERNS  
 
Only 63,071 practitioners in the U.S. have waivers permitting them to prescribe 
buprenorphine for OUD.129  Many of those practitioners seldom, if ever, use it.130  Federal 
regulations controlling the prescribing of buprenorphine for OUD are considered deterrents to 
greater use of the medication.131  More specifically, physicians without a federal waiver to 
prescribe buprenorphine for OUD report a concern that the DEA will intrude on their practice if 
they obtain a waiver.132  
 
DOJ raids of practitioners who prescribe buprenorphine for OUD exacerbate, rather than 
alleviate, apprehensions related to federal regulation and scrutiny.133  As Dr. Margaret Jarvis, a 
                                                





129 Practitioner and Program Data, SUBSTANCE ABUSE & MENTAL HEALTH SERVS. ADMIN. 
https://www.samhsa.gov/medication-assisted-treatment/training-materials-resources/physician-
program-data (last visited Jul. 17, 2019). 
130 Christine Vestal, Few Doctors Are Willing, Able to Prescribe Powerful Anti-Addiction Drugs, 
PEW CHARITABLE TRUSTS (Jan. 15, 2016), https://www.pewtrusts.org/en/research-and-
analysis/blogs/stateline/2016/01/15/few-doctors-are-willing-able-to-prescribe-powerful-anti-
addiction-drugs.  
131 Emily Cassel, This Drug Could Help End Opioid Addiction, VICE (June 9, 2017), 
https://tonic.vice.com/en_us/article/43yp3g/this-drug-could-help-end-opioid-addiction.  
132 C. HOLLY A. ANDRILLA ET AL., OVERCOMING BARRIERS TO PRESCRIBING BUPRENORPHINE FOR 
THE TREATMENT OF OPIOID USE DISORDER: RECOMMENDATIONS FROM RURAL PHYSICIANS, 35 J. 
RURAL HEALTH 113, 117 (2019). 
133 Szalavitz, supra note 62. 
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psychiatrist and the vice president of ASAM, said after the raids of ASAM physicians Gitlow 
and Reach, “[i]n terms of having a chilling effect, this is bad.”134  The chilling effect of DOJ 
raids of OUD treatment providers undermines the federal government’s express goal of 
increasing the number of practitioners who prescribe them.135  
 
C. TWO KEY ELEMENTS OF CONTROLLED SUBSTANCE PRESCRIBING CASES ARE MEDICAL IN 
NATURE 
 
Under the federal Controlled Substances Act (CSA), the DOJ has the authority to 
investigate and prosecute controlled medication prescribers and dispensers.136  In cases involving 
prescribers brought under the CSA, federal courts determine criminal liability based on whether 
(1) the practitioner knowingly and intentionally furnished a prescription for a controlled 
medication; (2) the practitioner’s behavior served a “legitimate medical purpose”; and (3) the 
practitioner acted within “the usual course of medical practice.”137  Steps two and three of this 
test require an assessment of the medical condition of the individual who received the 
prescription and an evaluation of whether the treatment the professional provided to the patient 
was consistent with the standards of the profession.138  
 
III. POLICY RECOMMENDATION  
 
A. LICENSING BOARDS ARE WELL EQUIPPED TO EVALUATE MEDICAL NEED AND PATIENT 
CARE  
 
Broadly speaking, the mission of state health-profession licensing boards is to keep 
patients safe.139  These boards are typically composed of licensed practitioner and non-
practitioner members.140  Most health-profession licensing boards have a staff that includes an 
executive director, investigators, and attorneys, with legal services provided by the state’s 
                                                
134 Id. 
135 Moraff, supra note 81. 
136 MICHAEL C. BARNES & STACEY L. SKLAVER, ACTIVE VERIFICATION AND VIGILANCE: A 
METHOD TO AVOID CIVIL AND CRIMINAL LIABILITY WHEN PRESCRIBING CONTROLLED 
SUBSTANCES, 15 DEPAUL J. HEALTH CARE L. 93, 102 (2013). 
137 Id. at 103. 
138 Id. at 104. 
139 FED’N ST. MED. BOARDS, http://www.fsmb.org/ (last visited Jul. 17, 2019). 
140 Consumer FAQ, FED’N ST. MED. BOARDS, https://www.fsmb.org/consumer-faq/ (last visited 
Jul. 17, 2019). 
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attorney general office.141  Complaints or reports regarding health professionals are often 
anonymous and may be submitted to licensing boards by patients, caregivers, law enforcement, 
or concerned citizens, such as members of the news media.142  
 
 When a board receives an allegation regarding a licensed health professional potentially 
violating the law, regulations, or the medical standard of care, the board’s staff reviews the 
allegations and decides whether to investigate.143  Licensed practitioners have a right to due 
process when allegations against them are brought to the licensing board.144  In instances when 
the alleged conduct threatens patients with immediate harm, such as sexual misconduct or 
substance-related impairment, boards may issue an emergency suspension of the practitioner’s 
license until an investigation of the practitioner is completed.145  
 
After an investigation, the staff submits its findings to the board for review, possible 
hearings, and action.146  The board may impose discipline, including suspension or revocation of 
the license to practice.147  Final board orders may include findings of fact, conclusions of law, 
and final decrees or stipulations.148 
 
Health-profession licensing boards’ responsibilities include providing guidance to 
licensees on best practices or specific medical topics.149  Their members and staff have 
knowledge of the medical standard of care and best practices, and the vast majority of them have 
non-practitioner members to represent the interests of the public.150  Licensing boards’ processes 
provide accused professionals investigative transparency and an opportunity to be heard.  For 
these reasons, licensing boards should be the first to investigate allegations in which medical 
                                                
141 Id. 
142 See Understanding the Enforcement Process, VA. DEPT’T OF HEALTH PROFS., 
https://www.dhp.virginia.gov/media/dhpweb/docs/enforcement/enfBrochure.pdf.  
143 See id. 
144 U.S. Medical Regulatory Trends and Actions, FED’N ST. MED. BOARDS, 
http://www.fsmb.org/siteassets/advocacy/publications/us-medical-regulatory-trends-actions.pdf 
(last visited July 17, 2019).  
145 Id.  
146 See Understanding the Enforcement Process, supra note 140. 
147 Consumer FAQ, supra note 138. 
148 U.S. Medical Regulatory Trends and Actions, supra note 142. 
149 Id. 
150 Id.  
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need and patient care are at issue.  Given that criminal liability in federal CSA prescribing cases 
hinges upon whether the prescriber’s behavior served a legitimate medical need and whether the 
practitioner provided patient care consistent within the ordinary course of professional practice, 




B. CONGRESS SHOULD REQUIRE A STATE MEDICAL LICENSING BOARD DETERMINATION 
BEFORE FEDERAL AGENTS MAY INVESTIGATE A PRESCRIBER 
 
Congress should amend federal law to require that federal investigators and prosecutors 
obtain a referral from a state professional licensing board before instituting, aiding in, or 
defending a criminal investigation, indictment, or prosecution or civil action against a state-
licensed health care professional or pharmacist in which medical need or patient care, including 
the prescribing or dispensing of controlled medications, is at issue.  The licensing board referral 
should be premised upon a final order of the full board whose factual findings expressly include 
misconduct that warrants criminal investigation.   
 
C. STATE LEGISLATURES SHOULD REQUIRE A LICENSING BOARD REFERRAL BEFORE LAW 
ENFORCEMENT MAY INVESTIGATE A PRESCRIBER 
 
Similarly, state legislatures should amend their laws to require that state law enforcement, 
including the attorney general and political subdivision prosecutors, sheriffs’ offices, and police 
departments, obtain a referral from a state professional licensing board before instituting, aiding 
in, or defending a criminal investigation, indictment, or prosecution or civil action against a 
state-licensed health care professional or pharmacist in which medical need or patient care, 
including the prescribing or dispensing of controlled medications, is at issue.  The licensing 
board referral should be premised upon a final order of the full board whose factual findings 
expressly include misconduct that warrants criminal investigation.   
  
D. CONGRESS SHOULD AUTHORIZE AND APPROPRIATE FEDERAL FUNDING FOR STATE 
HEALTH-PROFESSION LICENSING BOARDS  
 
In recent years, Congress has allocated a significant amount of federal funding in 
response to the overdose crisis.151  Overall funding for treatment initiatives increased from $7.9 
billion in fiscal year (FY) 2013 to $10.6 billion in FY 2017.152  Prevention efforts were funded at 
                                                
151 LISA N. SACCO & ERIN BAGALMAN, R44987, CONG. RESEARCH SERV., THE OPIOID EPIDEMIC 
AND FEDERAL EFFORTS TO ADDRESS IT: FREQUENTLY ASKED QUESTIONS (Oct. 18, 2017). 
152 Economic Aspects of the Opioid Crisis: Hearing Before the U.S. Cong. Joint Econ. Comm., 
115th Cong. (2017) (statement of Lisa N. Sacco, Analyst, Congressional Research Service). 
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around $1.5 billion in FY 2017, up from $1.27 billion in FY 2013.153  Law enforcement funding 
for opioid-related efforts increased from $8.8 billion in FY 2013 to $9.3 billion in FY 2017.154  
 
To support state professional licensing boards in expeditiously investigating complaints, 
disciplining or rehabilitating noncompliant health professionals, and referring potentially 
criminal misconduct to law enforcement, Congress should redirect federal opioid-related funding 
away from the DOJ to HHS. HHS should then provide grants to states to bolster the budgets of 
health-profession licensing boards.  Directing to state licensing boards $930 million, just ten 
percent of FY 2017 funding for law enforcement efforts to reduce opioid abuse, would create a 
“surge,” radically bolstering state-board resources.  This approach would enable state health-
profession licensing boards to efficiently investigate and, if necessary, act upon allegations in 




Prescription-opioid-related overdose deaths are on the decline while illicit-opioid-related 
deaths ravage families and communities.  Nonetheless, the federal government continues to focus 
largely on reducing access to prescription opioid medications.  As part of this effort, the DOJ has 
instituted several initiatives targeting health care providers, including a 45-day “surge” in which 
the DOJ took action against 365 individuals whose conduct it deemed unlawful.   
 
Not all health care professionals subject to the DOJ’s searches and seizures are “dirty 
docs.”  In fact, some of them are nationally recognized leaders not just in pain management, but 
also in addiction medicine.155  
 
The DOJ’s indiscriminate raids of health care providers can put patients’ lives at risk by 
leaving them without access to medically necessary treatments, destroy the livelihoods of 
physicians and other professionals who have not been convicted of or even charged with a crime, 
and discourage other health care providers from practicing in the same field of medicine.156  This 
chilling effect is especially troublesome given that Congress has prioritized increasing the 
number of health care providers who prescribe buprenorphine to treat OUD.157  
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Licensing boards are made up of licensed practitioners and staffed by individuals with 
specialized knowledge of the health professions.  Their investigative processes are transparent 
and provide the accused an opportunity to be heard.  A referral from a state health-profession 
licensing board should, therefore, be a prerequisite to law enforcement investigations of health 
care providers in which medical need and patient care are at issue.  
 
 
